The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
September 4, 2019
-
BUSINESS Astellas Grabs Global Rights to RIKEN’s aAVC Technology in Oncology
September 3, 2019
-
BUSINESS Astellas Revving Up Digital Transformation Drive, Expands Scope of Data to Derive Values
September 2, 2019
-
TRENDS Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up
August 30, 2019
-
REGULATORY MHLW Panel Puts a Hold on Possible World’s 1st OK for Ono’s Cancer Cachexia Drug
August 30, 2019
-
ORGANIZATION Japan Doctors’ Group Raps Payer Proposal to Scrap Coverage for Pollen Allergy Drugs
August 29, 2019
-
REGULATORY Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
August 28, 2019
-
REGULATORY Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
August 28, 2019
-
REGULATORY Tagrisso to Face 15% Price Cut in November Because It Sold Too Well
August 27, 2019
-
ORGANIZATION Kenporen Proposes Excluding OTC-Like Pollinosis Drugs from Health Coverage, Expecting Annual Savings of 60 Billion Yen
August 26, 2019
-
REGULATORY Japan to Set Up Dedicated Team to Expedite Review of Sakigake-Designated Cell/Gene Therapies
August 23, 2019
-
REGULATORY Tecentriq Wins Japan Nod for SCLC as 1st Checkpoint Drug for This Use
August 23, 2019
-
BUSINESS Price Revision Rates in October Re-Pricing Vary in Crowded DPP-4 Class: Survey
August 22, 2019
-
BUSINESS Frontloaded Price Cuts before Regular April Revision Hurts, Say Drug Makers
August 21, 2019
-
REGULATORY No PMP for Tecentriq, but Prices Rise for All 5 Checkpoint Drugs in Tax Hike Re-Pricing
August 21, 2019
-
BUSINESS Tax Hike Re-Pricing Slams Small Pharma and Gx Players, Impact Milder for Big Firms: Survey
August 20, 2019
-
REGULATORY Kymriah, All Checkpoint Drugs but Tecentriq to Get Price Maintenance Premium in October Re-Pricing
August 20, 2019
-
BUSINESS Sumitomo Dainippon Flip-Plops on Sales Force Cutback as It Ramps Up Diabetes Push
August 19, 2019
-
REGULATORY First “Post-Nesp” Renal Anemia Med Could Land Japan Approval in September
August 16, 2019
-
REGULATORY Japan OKs Zetia Generic, Possibly AG, towards December Listing; No Entry for Lyrica This Time
August 16, 2019
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…